INTERIM
REPORT
29 February 2020
DIRECTORS’ RESPONSIBILITY STATEMENT In respect of the Interim Report for the six months ended 29 February 2020, we confirm that, to the best of our knowledge:
•
•
The Interim Report has not been reviewed or audited by the Company’s auditors.
•
the interim financial information contained within has been prepared in accordance with IAS 34 “Interim Financial Reporting”; and gives a true and fair view of the assets, liabilities, financial position and profit and loss of the Company as at 29 February 2020, as required by the Financial Conduct Authority’s Disclosure Guidance and Transparency Rule 4.2.4R;
the Interim Report includes a fair review of the information concerning related party transactions as required by Disclosure Guidance and Transparency Rule 4.2.8R.
The Interim Report for the six months ended 29 February 2020 was approved by the Board and the above Responsibility Statement has been signed on its behalf by:
the Interim Report includes a fair review, as required by Disclosure Guidance and Transparency Rule 4.2.7R, of important events that has occurred during the six months ended 29 February 2020 and their impact on the interim financial information and a description of the principal risks and uncertainties for the remaining six months of the financial year; and
International Biotechnology Trust plc | Directors’ Responsibility Statement
JOHN ASTON | Chairman 24 April 2020
15
